A Phase II Study of Erlotinib for previously treated Non-small cell Lung Cancer Patients without Epidermal Growth Factor Receptor Mutation.

Trial Profile

A Phase II Study of Erlotinib for previously treated Non-small cell Lung Cancer Patients without Epidermal Growth Factor Receptor Mutation.

Completed
Phase of Trial: Phase II

Latest Information Update: 31 Oct 2014

At a glance

  • Drugs Erlotinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 May 2012 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
    • 18 Feb 2011 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.
    • 07 Nov 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top